Hypoactive Sexual Desire Disorder (HSDD) Treatment Market

Market Insights

The hypoactive sexual desire disorder treatment market is set to expand at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2019 to 2027. Hypoactive sexual desire disorder (HSDD) can be primary, secondary, lifelong, or situational; currently, physicians worldwide are employing either psychotherapy or pharmacotherapy for its treatment.

The recent approval of Bremelanotide (Vyleesi) will propel the HSDD market’s growth in the near future. Currently, two drugs, such as Prasterone 6.5 mg vaginal insert and BP101, are under phase 3 clinical trials being investigated for their safety and efficacy in treating HSDD.

Market Synopsis

A multifunctional serotonin agonist and antagonist pharmacodynamic profile increase the popularity of flibanserin for treating HSDD.

Hypoactive sexual desire disorder (HSDD) is the absence of sexual thoughts and fantasies that causes low libido and sex drive in the female population worldwide. The neurochemical basis associated with HSDD is not fully understood, but low sexual desire has been associated with hyperfunction inhibition, hypofunctional excitation, or a combination of both regulated by neuromodulators. Fluctuating sex hormones during the menstrual cycle are also a chief contributing factor to the occurrence of HSDD in the female population worldwide.

The diagnosis of HSDD is challenging, and physicians rely on pharmacotherapy and psychotherapy for its treatment. The PLISSIT model (Permission, Limited Information, Specific Suggestions, and Intensive Therapy) aids in the initial screening of HSDD. Cognitive behavior therapy is offered to patients responding to counseling sessions with a sexual therapist. In pharmacotherapy, antidepressants such as bupropion and buspirone have been used as off-label treatments for HSDD in women showing low sexual drive associated with anxiety and depression.

Testosterone transdermal patches are used as an off-label treatment for premenopausal and postmenopausal women with HSDD. Flibanserin is currently the only drug approved by the USFDA for treating HSDD in premenopausal women by decreasing serotonin activity and increasing norepinephrine and dopamine activity simultaneously.

Increasing stress and fluctuating hormones are responsible for low sexual drive in the female population in the North American region.

North America, with a share of 38.5%, is currently the clear leader in the regional segment of the hypoactive sexual desire disorder (HSDD) treatment market. The chief contributing factors for the growing incidence of low sex drive in the female population in the North American region are increasing stress in daily life and fluctuating hormones associated with the menstrual cycle.

The presence of pharmaceutical companies engaged in drug development for treating HSDD, such as Allergan, Plc., AMAG Pharmaceuticals, S1 Biopharma, Inc., Sprout Pharmaceuticals, Inc., etc., further bolsters market growth in the region. Europe accounts for 32.4% of the market share owing to favorable reimbursement scenarios for drugs prescribed for the treatment of HSDD. Asia Pacific represents a 15.2% market share and is ready to register faster growth during the forecast period, primarily due to the rising incidence of stress in the working women population and developing healthcare infrastructure.

Historical and Forecast Period

This research report presents the analysis of each segment from 2017 to 2027, considering 2018 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market is segmented by therapy and by geography.

Pharmaceutical companies providing pharmacotherapy for treating hypoactive sexual desire disorder are AMAG Pharmaceuticals, Allergan, Plc., Ivix, LLX., EndoCeutics, Inc., Emotional Brain BV., S1 Biopharma, Inc., and Sprout Pharmaceuticals, Inc.

Key questions are answered in this report.

• What are the strategic collaborations, mergers, and acquisitions taking place in the HSDD treatment market?
• Which pharmaceutical companies are providing pharmacotherapy drugs for treating HSDD?
• What is the pathophysiology associated with HSDD and the treatment regimen adopted by physicians worldwide?
• What are the market size and CAGR of developed regional segments such as North America and Europe in the HSDD treatment market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Treatment
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global HSDDT Market Portraiture
2.2. Global HSDDT Market, by Therapy, 2018 (US$ Mn)
2.3. Global HSDDT Market, by Geography, 2018 (US$ Mn)

Chapter 3. Hypoactive Sexual Desire Disorder Treatment (HSDDT) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global HSDDT Market, by Key Players, 2018

Chapter 4. Global Hypoactive Sexual Desire Disorder Treatment (HSDDT) Market, by Therapy
4.1. Overview
4.2. Buspirone
4.3. Bupropion
4.4. Testosterone
4.5. Flibanserin
4.6. Bremelanotide
4.7. Cognitive Behavior Therapy
4.8. Pipeline Analysis
4.8.1. Phase III Drug
4.8.1.1. Prasterone 6.5 mg Vaginal Insert
4.8.1.2. BP101

Chapter 5. Global Hypoactive Sexual Desire Disorder Treatment (HSDDT) Market, by Geography
5.1. Overview
5.2. North America HSDDT Market Analysis, 2017 – 2027
5.2.1. North America HSDDT Market, by Therapy, 2017 – 2027 (US$ Mn)
5.2.2. North America HSDDT Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe HSDDT Market Analysis, 2017– 2027
5.3.1. Europe HSDDT Market, by Therapy, 2017 – 2027 (US$ Mn)
5.3.2. Europe HSDDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific HSDDT Market Analysis, 2017 – 2027
5.4.1. Asia Pacific HSDDT Market, by Therapy, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific HSDDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America HSDDT Market Analysis, 2017 – 2027
5.5.1. Latin America HSDDT Market, by Therapy, 2017 – 2027 (US$ Mn)
5.5.2. Latin America HSDDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa HSDDT Market Analysis, 2017 – 2027
5.6.1. MEA HSDDT Market, by Therapy, 2017 – 2027 (US$ Mn)
5.6.2. MEA HSDDT Market, by Region, 2017– 2027 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. AMAG Pharmaceuticals
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Allergan, Plc.
6.3. Ivix LLX
6.4. EndoCeutics, Inc.
6.5. Emotional Brain BV
6.6. S1 Biopharma, Inc.
6.7. Sprout Pharmaceuticals, Inc.

List of Figures

FIG. 1 Hypoactive Sexual Desire Disorder Treatment (HSDDT) Market: Research Methodology
FIG. 2 HSDDT: Market Segmentation
FIG. 3 Global HSDDT Market, by Therapy, 2018 (US$ Mn)
FIG. 4 Global HSDDT Market, by Geography, 2018 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2018
FIG. 6 Competitive Analysis: Global HSDDT Market, by Key Players, 2018
FIG. 7 Global Buspirone Market for HSDDT, 2017 – 2027 (US$ Mn)
FIG. 8 Global Bupropion Market for HSDDT, 2017 – 2027 (US$ Mn)
FIG. 9 Global Testosterone Market for HSDDT, 2017 – 2027 (US$ Mn)
FIG. 10 Global Flibanserin Market for HSDDT, 2017– 2027 (US$ Mn)
FIG. 11 Global Bremelanotide Market for HSDDT, 2017 – 2027 (US$ Mn)
FIG. 12 Global Cognitive Behavior Therapy Market for HSDDT, 2017 – 2027 (US$ Mn)
FIG. 13 U.S. HSDDT Market, 2017 – 2027 (US$ Mn)
FIG. 14 Canada HSDDT Market, 2017 – 2027 (US$ Mn)
FIG. 15 U.K. HSDDT Market, 2017 – 2027 (US$ Mn)
FIG. 16 Germany HSDDT Market, 2017 – 2027 (US$ Mn)
FIG. 17 Rest of Europe HSDDT Market, 2017 – 2027 (US$ Mn)
FIG. 18 China HSDDT Market, 2017– 2027 (US$ Mn)
FIG. 19 Japan HSDDT Market, 2017 – 2027 (US$ Mn)
FIG. 20 Rest of Asia Pacific HSDDT Market, 2017 – 2027 (US$ Mn)
FIG. 21 Brazil HSDDT Market, 2017 – 2027 (US$ Mn)
FIG. 22 Mexico HSDDT Market, 2017 – 2027 (US$ Mn)
FIG. 23 Rest of Latin America HSDDT Market, 2017 – 2027 (US$ Mn)
FIG. 24 GCC HSDDT Market, 2017 – 2027 (US$ Mn)
FIG. 25 Rest of Middle East and Africa HSDDT Market, 2017 – 2027 (US$ Mn)

List of Tables

TABLE 1 Global Hypoactive Sexual Desire Disorder Treatment (HSDDT) Market Portraiture
TABLE 2 Global HSDDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 3 Global HSDDT Market, by Geography, 2017 – 2027 (US$ Mn)
TABLE 4 North America HSDDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 5 North America HSDDT Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 6 Europe HSDDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 7 Europe HSDDT Market, by Country/Region, 2017– 2027 (US$ Mn)
TABLE 8 Asia Pacific HSDDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 9 Asia Pacific HSDDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Latin America HSDDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 11 Latin America HSDDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 12 Middle East and Africa HSDDT Market, by Therapy, 2017– 2027 (US$ Mn)
TABLE 13 Middle East and Africa HSDDT Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 14 AMAG Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 Allergan, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 Ivix LLX: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 EndoCeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 Emotional Brain BV: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 S1 Biopharma, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Sprout Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)